These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29447370)

  • 61. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
    Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Up-titration of allopurinol in patients with gout.
    Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inpatient management of gout in a New Zealand hospital: a retrospective audit.
    Kennedy NJ; Healy PJ; Harrison AA
    Int J Rheum Dis; 2016 Feb; 19(2):205-10. PubMed ID: 25873399
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimising gout treatment: insights from a nurse-led cohort study.
    Rasmussen C; Larsen JW; Christensen HM; Larsen MB; Thomsen AM; Leishmann T; Kragh J; Nielsen GL
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663881
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 73. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Bardin T; Pascual E; Barskova V; Conaghan P; Gerster J; Jacobs J; Leeb B; Lioté F; McCarthy G; Netter P; Nuki G; Perez-Ruiz F; Pignone A; Pimentão J; Punzi L; Roddy E; Uhlig T; Zimmermann-Gòrska I;
    Ann Rheum Dis; 2006 Oct; 65(10):1312-24. PubMed ID: 16707532
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management.
    Singh JA; Alpert MD; Kerr G
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1306-11. PubMed ID: 20235197
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
    Koide H; Hira D; Tsujimoto M; Katsube Y; Minegaki T; Uzu T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
    Biol Pharm Bull; 2017; 40(5):681-686. PubMed ID: 28458354
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.
    Yip RM; Cheung TT; So H; Chan JP; Ho CT; Tsang HH; Yu CK; Wong PC;
    Clin Rheumatol; 2023 Aug; 42(8):2013-2027. PubMed ID: 37014501
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia.
    Terrill M; Riordan J
    Int J Rheum Dis; 2018 Feb; 21(2):517-522. PubMed ID: 28544467
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
    Hilmi BA; Asmahan MI; Rosman A
    Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.